

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting
FDA White Oak Campus, Building 31 Conference Center, the Great Room (Rm. 1503)
10903 New Hampshire Avenue, Silver Spring, Maryland
June 20, 2017

DRAFT MEETING ROSTER

DESIGNATED FEDERAL OFFICER (Non-Voting)

LaToya Bonner, PharmD

Division of Advisory Committee and Consultant Management
Office of Executive Programs, CDER, FDA

ENDOCRINOLOGICAND METABOLIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Michael Blaha, MD, MPH

Assistant Professor, Cardiology and Epidemiology
Director of Clinical Research
Johns Hopkins Ciccarone Center for the Prevention
of Heart Disease
Baltimore, Maryland

Kenneth D. Burman, MD

Chief, Endocrine Section
Medstar Washington Hospital Center
Professor, Department of Medicine
Georgetown University
Washington, District of Columbia

Diana Hallare, MPH

(Consumer Representative)
Visalia, California

James D. Neaton, PhD

Professor of Biostatistics
Division of Biostatistics
Coordinating Centers for Biometric Research
School of Public Health
University of Minnesota
Minneapolis, Minnesota

Daniel Budnitz, MD, MPH

CAPT, US Public Health Service
Director, Medication Safety Program
Division of Healthcare Quality Promotion
Centers for Disease Control and Prevention
Atlanta, Georgia

Brendan M. Everett, MD, MPH

Assistant Professor of Medicine
Harvard Medical School
Director, General Cardiology Inpatient Service
Brigham and Women's Hospital
Boston, Massachusetts

Cecilia C. Low Wang, MD

Associate Professor of Medicine
Associate Director, Fellowship/Education, Division of
Endocrinology, Diabetes, and Metabolism
University of Colorado Anschutz Medical Campus
School of Medicine
Director, Glucose Management Team
University of Colorado Hospital
Medical Safety Officer, CPC Clinical Research
Aurora, Colorado

Peter W. F. Wilson, MD

(Chairperson)
Director, Epidemiology and Genomic Medicine
Atlanta Veterans Administration Medical Center
Professor of Medicine and Public Health
Emory University
Emory Clinical Cardiovascular Research Institute
Atlanta, Georgia

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting
June 20, 2017

DRAFT MEETING ROSTER (cont.)

**ENDOCRINOLOGIC AND METABOLIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)
(cont.)**

Susan Z. Yanovski, MD

Co-Director, Office of Obesity Research
Senior Scientific Advisor for Clinical Obesity
Research
National Institute of Diabetes and Digestive and
Kidney Diseases
National Institutes of Health (NIH)
Bethesda, Maryland

**ENDOCRINOLOGIC AND METABOLIC DRUGS ADVISORY COMMITTEE MEMBER (Non-
Voting)**

Reshma Kewalramani, MD, FASN

Senior Vice President, Late Development
Global Medicines Development and Medical
Affairs
Vertex Pharmaceuticals
Boston, Massachusetts

TEMPORARY MEMBERS (Voting)

Carmen J. Allegra, MD

Chief, Hematology and Oncology
University of Florida
Gainesville, Florida

Leslie Cho, MD, FACC, FSCAI

Section Head, Preventive Cardiology and
Rehabilitation
Director, Women's Cardiovascular Center
Cleveland Clinic
Cleveland, Ohio

James A. de Lemos, MD

Professor of Medicine
Kern Wildenthal MD, PhD
Distinguished Chair in Cardiology
UT Southwestern Medical Center
Dallas, Texas

Judith Fradkin, MD

Director, Division of Diabetes, Endocrinology and
Metabolic Diseases,
National Institute of Diabetes and Digestive and
Kidney Diseases, NIH
Bethesda, Maryland

Marvin A. Konstam, MD

Chief Physician Executive
The CardioVascular Center
Tufts Medical Center
Professor of Medicine
Tufts University School of Medicine
Boston, Massachusetts

Debra McCall, MBA

(Patient Representative)
Murrieta, California

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting
June 20, 2017

DRAFT MEETING ROSTER (cont.)

TEMPORARY MEMBERS (Voting) (cont.)

David Oakes, PhD

Professor of Biostatistics
University of Rochester Medical Center
Rochester, New York

Yves Rosenberg, MD

Branch Chief
Atherothrombosis and Coronary Artery Disease
Branch
Division of Cardiovascular Sciences
National Heart, Lung, and Blood Institute, NIH
Bethesda, Maryland

David C. Robbins, MD

Professor of Medicine
Director, University of Kansas Diabetes
Institute
University of Kansas School of Medicine
Kansas City, Kansas

Hanna Sanoff, MD, MPH

Section Chief of GI Medical Oncology
Associate Professor
Department of Medicine
Cancer Prevention and Control
Gastrointestinal Oncology Programs
University of North Carolina – Chapel Hill
Chapel Hill, North Carolina

FDA PARTICIPANTS (Non-Voting)

Jean-Marc Guettier, MD

Director
Division of Metabolism and Endocrinology Products
(DMEP)
Office of Drug Evaluation II (ODE-II)
Office of New Drugs (OND), CDER, FDA

Lisa Yanoff, MD

Clinical Team Leader
DMEP, ODE-II, OND, CDER, FDA

Julie Golden, MD

Clinical Reviewer
DMEP, ODE-II, OND, CDER, FDA

Tania Condarco, MD

Clinical Reviewer
DMEP, ODE-II, OND, CDER, FDA

Kiya Hamilton, PhD

Mathematical Statistician
Division of Biostatistics II (DB-II)
Office of Biostatistics (OB)
Office of Translational Sciences (OTS), CDER, FDA